Investigational antiarrhythmic agents: promising drugs in early clinical development

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;2015(36):2793–2867.
   Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;2016(37):2893–2962.
   Web of Science ®Google Scholar
• Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015;116:1887–1906.
   PubMed Web of Science ®Google Scholar
• Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 1990;65:42I–8I.
   PubMed Web of Science ®Google Scholar
• Fedeli U, Ferroni E, Pengo V. Mortality associated to atrial fibrillation still on the rise: United States, 1999 to 2014. Int J Cardiol. 2016;222:788–789.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry. Europace. 2014;16:308–319.
   PubMed Web of Science ®Google Scholar
• Dev S, Peterson PN, Wang Y, et al. Prevalence, correlates, and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement (from the National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2014;113:314–320.
   PubMed Web of Science ®Google Scholar
• Schleifer JW, Sorajja D, Shen WK. Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opin Pharmacother. 2015;16:2637–2651.
   PubMed Web of Science ®Google Scholar
• Qin D, Leef G, Alam MB, et al. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. J Cardiol. 2016;67:471–476.
   PubMed Web of Science ®Google Scholar
• Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552–1559.
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol. 2013;9:71–88.
   PubMedGoogle Scholar
• Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2016;13:36–47.
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483–1499.
   PubMed Web of Science ®Google Scholar
• Heijman J, Algalarrondo V, Voigt N, et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res. 2016;109:467–479.
   PubMed Web of Science ®Google Scholar
• Qu Z, Weiss JN. Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence. Annu Rev Physiol. 2015;77:29–55.
   PubMed Web of Science ®Google Scholar
• Bartos DC, Grandi E, Ripplinger CM. Ion channels in the heart. Compr Physiol. 2015;5:1423–1464.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Heijman J, Nattel S, et al. Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol. 2013;108:336.
   PubMed Web of Science ®Google Scholar
• Wagner S, Maier LS, Bers DM. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circ Res. 2015;116:1956–1970.
   PubMed Web of Science ®Google Scholar
• Comtois P, Kneller J, Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace. 2005;7(Suppl 2):10–20.
   PubMed Web of Science ®Google Scholar
• Abriel H, Rougier JS, Jalife J. Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death. Circ Res. 2015;116:1971–1988.
   PubMed Web of Science ®Google Scholar
• Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiol Rev. 2014;94:609–653.
   PubMed Web of Science ®Google Scholar
• Landstrom AP, Dobrev D, Wehrens XH. Calcium signaling and cardiac arrhythmias. Circ Res. 2017;120:1969–1993.
   PubMed Web of Science ®Google Scholar
• Chiamvimonvat N, Chen-Izu Y, Clancy CE, et al. Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. J Physiol. 2017;595:2229–2252.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wiedmann F, Voigt N, et al. Upregulation of K2P3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation. 2015;132:82–92.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wiedmann F, Zhou XB, et al. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J. 2017;38:1764–1774.
   Web of Science ®Google Scholar
• Zhang XD, Lieu DK, Chiamvimonvat N. Small-conductance Ca2+ -activated K+ channels and cardiac arrhythmias. Heart Rhythm. 2015;12:1845–1851.
   PubMed Web of Science ®Google Scholar
• Chang PC, Chen PS. SK channels and ventricular arrhythmias in heart failure. Trends Cardiovasc Med. 2015;25:508–514.
   PubMed Web of Science ®Google Scholar
• Simard C, Hof T, Keddache Z, et al. The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential. J Mol Cell Cardiol. 2013;59:11–19.
   PubMed Web of Science ®Google Scholar
• Cardiology TTFotWGoAotESo. The ‘Sicilian Gambit’. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J. 1991;12:1112–1131.
   PubMed Web of Science ®Google Scholar
• Karagueuzian HS, Pezhouman A, Angelini M, et al. Enhanced late Na and Ca currents as effective antiarrhythmic drug targets. Front Pharmacol. 2017;8:36.
   PubMed Web of Science ®Google Scholar
• Osadchii OE. Impact of Na+ channel blockers on transmural dispersion of refractoriness and arrhythmic susceptibility in guinea-pig left ventricle. Eur J Pharmacol. 2012;691:173–181.
   PubMed Web of Science ®Google Scholar
• Sager PT. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation. Am J Cardiol. 1998;82:20I–30I.
   PubMed Web of Science ®Google Scholar
• El-Haou S, Ford JW, Milnes JT. Novel K+ channel targets in atrial fibrillation drug development–where are we? J Cardiovasc Pharmacol. 2015;66:412–431.
   PubMed Web of Science ®Google Scholar
• Voigt N, Dobrev D. Atrial-selective potassium channel blockers. Card Electrophysiol Clin. 2016;8:411–421.
   PubMedGoogle Scholar
• Ravens U, Odening KE. Atrial fibrillation: therapeutic potential of atrial K+ channel blockers. Pharmacol Ther. 2016.
   PubMedGoogle Scholar
• Weirich J, Antoni H. Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Res Cardiol. 1998;93(Suppl 1):125–132.
   PubMed Web of Science ®Google Scholar
• Gillis AM. Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. Circulation. 2017;135:593–608.
   PubMed Web of Science ®Google Scholar
• Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol. 2012;60:539–545.
   PubMed Web of Science ®Google Scholar
• Darbar D. The role of pharmacogenetics in atrial fibrillation therapeutics: is personalized therapy in sight? J Cardiovasc Pharmacol. 2016;67:9–18.
   PubMed Web of Science ®Google Scholar
• Strauss DG, Vicente J, Johannesen L, et al. Common genetic variant risk score is associated with drug-induced prolongation and torsade QT de pointes risk: a pilot study. Circulation. 2017;135:1300–1310.
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Ghezelbash S, et al. Calcium handling abnormalities as a target for atrial fibrillation therapeutics: how close to clinical implementation? J Cardiovasc Pharmacol. 2015;66:515–522.
   PubMed Web of Science ®Google Scholar
• Mustroph J, Neef S, Maier LS. CaMKII as a target for arrhythmia suppression. Pharmacol Ther. 2016.
   PubMedGoogle Scholar
• Ford J, Milnes J, El Haou S, et al. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm. 2016;13:555–564.
   PubMed Web of Science ®Google Scholar
• Pavri BB, Greenberg HE, Kraft WK, et al. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. Circ Arrhythm Electrophysiol. 2012;5:1193–1201.
   PubMed Web of Science ®Google Scholar
• Olesen MS, Nielsen MW, Haunso S, et al. Atrial fibrillation: the role of common and rare genetic variants. Eur J Hum Genet. 2014;22:297–306.
   PubMed Web of Science ®Google Scholar
• Grandi E, Pandit SV, Voigt N, et al. Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res. 2011;109:1055–1066.
   PubMed Web of Science ®Google Scholar
• Wolkenberg SE, Nolt MB, Bilodeau MT, et al. Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. Bioorg Med Chem Lett. 2017;27:1062–1069.
   PubMed Web of Science ®Google Scholar
• Dobrev D, Ravens U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol. 2003;98:137–148.
   PubMed Web of Science ®Google Scholar
• Ellinwood N, Dobrev D, Morotti SGrandi E. Revealing kinetics and state-dependent binding properties of ikur-targeting drugs that maximize atrial fibrillation selectivity. Chaos. 2017; in press.
   Google Scholar
• Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current IK,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112:3697–3706.
   PubMed Web of Science ®Google Scholar
• Kiper AK, Rinne S, Rolfes C, et al. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? Pflugers Arch. 2015;467:1081–1090.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wiedmann F, Schweizer PA, et al. Inhibition of cardiac two-pore-domain K+ (K2P) channels–an emerging antiarrhythmic concept. Eur J Pharmacol. 2014;738:250–255.
   PubMed Web of Science ®Google Scholar
• Flaherty DP, Simpson DS, Miller M, et al. Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold. Bioorg Med Chem Lett. 2014;24:3968–3973.
   PubMed Web of Science ®Google Scholar
• Skarsfeldt MA, Jepps TA, Bomholtz SH, et al. pH-dependent inhibition of K2P3.1 prolongs atrial refractoriness in whole hearts. Pflugers Arch. 2016;468:643–654.
   PubMed Web of Science ®Google Scholar
• Decher N, Wemhoner K, Rinne S, et al. Knock-out of the potassium channel TASK-1 leads to a prolonged QT interval and a disturbed QRS complex. Cell Physiol Biochem. 2011;28:77–86.
   PubMed Web of Science ®Google Scholar
• Lugenbiel P, Wenz F, Syren P, et al. TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control. Basic Res Cardiol. 2017;112:8.
   PubMed Web of Science ®Google Scholar
• Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac “late sodium current. Pharmacol Ther. 2008;119:326–339.
   PubMed Web of Science ®Google Scholar
• Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for congenital long-QT syndrome type III: experimental and long-term clinical data. Circ Arrhythm Electrophysiol. 2016;9.
   Web of Science ®Google Scholar
• Curnis A, Salghetti F, Cerini M, et al. Ranolazine therapy in drug-refractory ventricular arrhythmias. J Cardiovasc Med (Hagerstown). 2017;18:534–538.
   PubMed Web of Science ®Google Scholar
• Yeung E, Krantz MJ, Schuller JL, et al. Ranolazine for the suppression of ventricular arrhythmia: a case series. Ann Noninvasive Electrocardiol. 2014;19:345–350.
   PubMed Web of Science ®Google Scholar
• Pulford BR, Kluger J. Ranolazine therapy in cardiac arrhythmias. Pacing Clin Electrophysiol. 2016;39:1006–1015.
   PubMed Web of Science ®Google Scholar
• Guerra F, Romandini A, Barbarossa A, et al. Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;227:284–291.
   PubMed Web of Science ®Google Scholar
• Gong M, Zhang Z, Fragakis N, et al. Role of ranolazine in the prevention and treatment of atrial fibrillation: a meta-analysis of randomized clinical trials. Heart Rhythm. 2017;14:3–11.
   PubMed Web of Science ®Google Scholar
• Zareba W, Daubert JP, Beck CA, et al. Late-breaking clinical trials II: ranolazine in high-risk icd patients (RAID) trial. Heart Rhythm. 2017;14:944.
   Google Scholar
• Belardinelli L, Liu G, Smith-Maxwell C, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther. 2013;344:23–32.
   PubMed Web of Science ®Google Scholar
• Koltun DO, Parkhill EQ, Elzein E, et al. Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine. Bioorg Med Chem Lett. 2016;26:3202–3206.
   PubMed Web of Science ®Google Scholar
• Zablocki JA, Elzein E, Li X, et al. Discovery of dihydrobenzoxazepinone (GS-6615) late sodium current inhibitor (Late INai), a phase II agent with demonstrated preclinical anti-ischemic and antiarrhythmic properties. J Med Chem. 2016.
   PubMed Web of Science ®Google Scholar
• Fuller H, Justo F, Nearing BD, et al. Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model. Heart Rhythm. 2016;13:1679–1686.
   PubMed Web of Science ®Google Scholar
• Bacic D, Carneiro JS, Bento AA, et al. Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model. Heart Rhythm. 2017;14:448–454.
   PubMed Web of Science ®Google Scholar
• Beat H End of the road for eleclazine and liberty HCM study 2016 [cited 2017 April 18]. Available from: https://hcmbeat.com/2016/12/27/end-of-the-road-for-eleclazine-and-liberty-hcm-study/
   Google Scholar
• Bers DM. Stabilizing ryanodine receptor gating quiets arrhythmogenic events in human heart failure and atrial fibrillation. Heart Rhythm. 2017;14:420–421.
   PubMed Web of Science ®Google Scholar
• Walweel K, Oo YW, Laver DR. The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene. Clin Exp Pharmacol Physiol. 2017;44:135–142.
   PubMed Web of Science ®Google Scholar
• Uchinoumi H, Yang Y, Oda T, et al. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. J Mol Cell Cardiol. 2016;98:62–72.
   PubMed Web of Science ®Google Scholar
• Hartmann N, Pabel S, Herting J, et al. Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. Heart Rhythm. 2017;14:412–419.
   PubMed Web of Science ®Google Scholar
• Zaza A, Rocchetti M. Calcium store stability as an antiarrhythmic endpoint. Curr Pharm Des. 2015;21:1053–1061.
   PubMed Web of Science ®Google Scholar
• Li N, Wang Q, Sibrian-Vazquez M, et al. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017;227:668–673.
   PubMed Web of Science ®Google Scholar
• Smith GL, MacQuaide N. The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT. Circ Res. 2015;116:1284–1286.
   PubMed Web of Science ®Google Scholar
• Williams AJ, Bannister ML, Thomas NL, et al. Questioning flecainide’s mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia. J Physiol. 2016;594:6431–6432.
   PubMed Web of Science ®Google Scholar
• Yang PC, Moreno JD, Jeng MT, et al. Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy. J Physiol. 2016;594:6433–6435.
   PubMed Web of Science ®Google Scholar
• Steele DS, Hwang HS, Knollmann BC. Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia. Cardiovasc Res. 2013;98:326–327.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011;17:1003–1009.
   PubMed Web of Science ®Google Scholar
• Tan Z, Xiao Z, Wei J, et al. Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia. Biochem J. 2016;473:4159–4172.
   PubMed Web of Science ®Google Scholar
• Dobrev D, Wehrens XH. Role of RyR2 phosphorylation in heart failure and arrhythmias: controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res. 2014;114:1311–1319. discussion 9.
   PubMed Web of Science ®Google Scholar
• Thireau J, Farah C, Bouly M, et al. Abstract 18592: anti-arrhythmic effect of a novel rycal, S44121 /Arm036, in a post-myocardial infarction mouse model of heart failure. Circulation. 2014;130:A18592.
   Google Scholar
• Zhong X, Sun B, Vallmitjana A, et al. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts. Biochem J. 2016;473:3951–3964.
   PubMed Web of Science ®Google Scholar
• Xu Y, Tuteja D, Zhang Z, et al. Molecular identification and functional roles of a Ca2+-activated K+ channel in human and mouse hearts. J Biol Chem. 2003;278:49085–49094.
   PubMed Web of Science ®Google Scholar
• Qi XY, Diness JG, Brundel BJ, et al. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation. 2014;129:430–440.
   PubMed Web of Science ®Google Scholar
• Zhou XB, Sun Q, Voigt N, et al. Increased trafficking of small-conductance Ca2+-activated K plus channels to plasma membrane modulates action potential duration in human paroxysmal atrial fibrillation. Eur Heart J. 2014;35:183.
   Web of Science ®Google Scholar
• Skibsbye L, Poulet C, Diness JG, et al. Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. Cardiovasc Res. 2014;103:156–167.
   PubMed Web of Science ®Google Scholar
• Simo-Vicens R, Sauter DRP, Grunnet M, et al. Effect of antiarrhythmic drugs on small conductance calcium - activated potassium channels. Eur J Pharmacol. 2017;803:118–123.
   PubMed Web of Science ®Google Scholar
• Kim TY, Terentyeva R, Roder KH, et al. SK channel enhancers attenuate Ca2+-dependent arrhythmia in hypertrophic hearts by regulating mito-ROS-dependent oxidation and activity of RyR. Cardiovasc Res. 2017;113:343–353.
   PubMed Web of Science ®Google Scholar
• Inoue R, Jensen LJ, Shi J, et al. Transient receptor potential channels in cardiovascular function and disease. Circ Res. 2006;99:119–131.
   PubMed Web of Science ®Google Scholar
• Harada M, Luo X, Qi XY, et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation. 2012;126:2051–2064.
   PubMed Web of Science ®Google Scholar
• Chubanov V, Ferioli S, Gudermann T. Assessment of TRPM7 functions by drug-like small molecules. Cell Calcium. 2017.
   PubMedGoogle Scholar
• Zhang YH, Wu HJ, Che H, et al. Functional transient receptor potential canonical type 1 channels in human atrial myocytes. Pflugers Arch. 2013;465:1439–1449.
   PubMed Web of Science ®Google Scholar
• Guinamard R, Bouvagnet P, Hof T, et al. TRPM4 in cardiac electrical activity. Cardiovasc Res. 2015;108:21–30.
   PubMed Web of Science ®Google Scholar
• Hof T, Liu H, Salle L, et al. TRPM4 non-selective cation channel variants in long QT syndrome. BMC Med Genet. 2017;18:31.
   PubMed Web of Science ®Google Scholar
• Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014;66:676–814.
   PubMed Web of Science ®Google Scholar
• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212–1223.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Nagarakanti R, Lubinski A, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012;34:1–9.
   PubMed Web of Science ®Google Scholar
• Heijman J, Heusch G, Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol. 2013;7:127–140.
   PubMedGoogle Scholar
• Piccini JP, Pritchett EL, Davison BA, et al. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Heart Rhythm. 2016;13:1777–1783.
   PubMed Web of Science ®Google Scholar
• Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ Arrhythm Electrophysiol. 2015;8:1048–1056.
   PubMed Web of Science ®Google Scholar
• Hartmann N, Mason FE, Braun I, et al. The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology. J Mol Cell Cardiol. 2016;94:95–106.
   PubMed Web of Science ®Google Scholar
• Aguilar M, Xiong F, Qi XY, et al. Potassium channel blockade enhances atrial fibrillation-selective antiarrhythmic effects of optimized state-dependent sodium channel blockade. Circulation. 2015;132:2203–2211.
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Belardinelli L, Antzelevitch C. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation. Heart Rhythm. 2015;12:836–844.
   PubMed Web of Science ®Google Scholar
• Kirchhoff JE, Diness JG, Sheykhzade M, et al. Synergistic antiarrhythmic effect of combining inhibition of Ca2+-activated K+ (SK) channels and voltage-gated Na+ channels in an isolated heart model of atrial fibrillation. Heart Rhythm. 2015;12:409–418.
   PubMed Web of Science ®Google Scholar